## Gioacchino Leandro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/777353/publications.pdf

Version: 2024-02-01

208 papers 15,584 citations

69 h-index 118 g-index

209 all docs

209 docs citations

times ranked

209

12522 citing authors

#	Article	IF	CITATIONS
1	Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. Journal of Hepatology, 2003, 39, 239-244.	3.7	806
2	A Comparison of Five Maintenance Therapies for Reflux Esophagitis. New England Journal of Medicine, 1995, 333, 1106-1110.	27.0	542
3	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology, 2006, 130, 1636-1642.	1.3	517
4	Development and Validation of a Multidimensional Prognostic Index for One-Year Mortality from Comprehensive Geriatric Assessment in Hospitalized Older Patients. Rejuvenation Research, 2008, 11, 151-161.	1.8	397
5	Gastric Dysplasia. American Journal of Surgical Pathology, 2000, 24, 167-176.	3.7	343
6	Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology, 1997, 25, 754-758.	7.3	329
7	Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology, 1999, 30, 612-622.	7.3	320
8	Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Alimentary Pharmacology and Therapeutics, 2002, 16, 1249-1259.	3.7	306
9	Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet, The, 1999, 354, 1053-1060.	13.7	296
10	Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. Journal of Hepatology, 2002, 36, 263-270.	3.7	290
11	Sequential Therapy or Triple Therapy for Helicobacter pylori Infection. American Journal of Gastroenterology, 2009, 104, 3069-3079.	0.4	254
12	Open versus laparoscopic cholecystectomy in acute cholecystitis. Systematic review and meta-analysis. International Journal of Surgery, 2015, 18, 196-204.	2.7	252
13	Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology, 2009, 49, 1236-1244.	7.3	248
14	Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut, 2004, 53, 406-412.	12.1	246
15	Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. Gastroenterology, 1994, 107, 1288-1296.	1.3	240
16	Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology, 2009, 104, 514-524.	0.4	239
17	Risk factors, Sequential Organ Failure Assessment and Model for End-stage Liver Disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Alimentary Pharmacology and Therapeutics, 2006, 23, 883-893.	3.7	232
18	Topographic patterns of intestinal metaplasia and gastric cancer. American Journal of Gastroenterology, 2000, 95, 1431-1438.	0.4	221

#	Article	IF	CITATIONS
19	βâ€Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a metaâ€analysis. Liver International, 2009, 29, 1189-1193.	3.9	207
20	A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut, 2000, 46, 597-600.	12.1	204
21	Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointestinal Endoscopy, 2000, 51, 1-7.	1.0	199
22	Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Digestive Diseases and Sciences, 2000, 45, 68-76.	2.3	188
23	Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: A controlled study. Journal of Hepatology, 2007, 46, 206-212.	3.7	188
24	Peginterferon Alfa-2a Plus Ribavirin Is More Effective Than Peginterferon Alfa-2b Plus Ribavirin for Treating Chronic Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 116-122.	1.3	175
25	The long term outcome of gastric non-invasive neoplasia. Gut, 2003, 52, 1111-1116.	12.1	167
26	Genetic Susceptibility to Nonsteroidal Anti-Inflammatory Drug–Related Gastroduodenal Bleeding: Role of Cytochrome P450 2C9 Polymorphisms. Gastroenterology, 2007, 133, 465-471.	1.3	161
27	Chronic hepatitis C in children: The pathological and clinical spectrum. Gastroenterology, 1998, 115, 1525-1529.	1.3	160
28	Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge. Nutrients, 2016, 8, 84.	4.1	155
29	Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointestinal Endoscopy, 2002, 56, 488-495.	1.0	151
30	Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. Journal of Hepatology, 2005, 42, 41-46.	3.7	151
31	Multidimensional Prognostic Index Based on a Comprehensive Geriatric Assessment Predicts Short-Term Mortality in Older Patients With Heart Failure. Circulation: Heart Failure, 2010, 3, 14-20.	3.9	146
32	Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori Infection. Digestion, 2013, 88, 33-45.	2.3	141
33	Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointestinal Endoscopy, 2002, 56, 488-495.	1.0	134
34	Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointestinal Endoscopy, 2007, 65, 624-632.	1.0	130
35	Alexithymia as Predictor of Treatment Outcome in Patients with Functional Gastrointestinal Disorders. Psychosomatic Medicine, 2003, 65, 911-918.	2.0	124
36	Fibrosis in Chronic Hepatitis C Acquired in Infancy: Is It Only a Matter of Time?. American Journal of Gastroenterology, 2003, 98, 660-663.	0.4	121

#	Article	IF	CITATIONS
37	Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver International, 2011, 31, 730-739.	3.9	120
38	Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology, 2001, 39, 119-124.	2.9	113
39	A Curcuminâ€Based 1â€Week Triple Therapy for Eradication of <i>Helicobacter pylori</i> Infection: Something to Learn From Failure?. Helicobacter, 2007, 12, 238-243.	3.5	111
40	Transjugular liver biopsy: how good is it for accurate histological interpretation?. Gut, 2006, 55, 1789-1794.	12.1	109
41	Clinical Features of Reflux Esophagitis in Older People: A Study of 840 Consecutive Patients. Journal of the American Geriatrics Society, 2006, 54, 1537-1542.	2.6	107
42	Natural History and Outcome of Hepatic Vascular Malformations in a Large Cohort of Patients with Hereditary Hemorrhagic Teleangiectasia. Digestive Diseases and Sciences, 2011, 56, 2166-2178.	2.3	106
43	Metaâ€nnalysis: the outcome of antiâ€viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 397-404.	3.7	104
44	Thromboelastography with citrated blood. Blood Coagulation and Fibrinolysis, 2004, 15, 103-107.	1.0	102
45	Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease. Digestive Diseases and Sciences, 2005, 50, 581-586.	2.3	102
46	Pegylatedâ€interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and metaâ€analysis of prospective controlled studies. Journal of Viral Hepatitis, 2008, 15, 699-709.	2.0	102
47	Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Alimentary Pharmacology and Therapeutics, 1998, 12, 237-245.	3.7	96
48	Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. Journal of Hepatology, 2002, 36, 799-804.	3.7	96
49	Long-term follow-up of achalasia patients treated with botulinum toxin. Digestive and Liver Disease, 2002, 34, 105-110.	0.9	95
50	Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transplantation, 2005, $11$ , 386-395.	2.4	95
51	Natural course of acute hepatitis C: a long-term prospective study. Digestive and Liver Disease, 2003, 35, 104-113.	0.9	93
52	Early versus late surgery for ileo aecal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 1303-1312.	3.7	90
53	The sup > 13 / sup > C-urea breath test as a predictor of intragastric bacterial load and severity of si> Helicobacter pylori / i> gastritis. Scandinavian Journal of Clinical and Laboratory Investigation, 1998, 58, 19-28.	1.2	88
54	High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Digestive Diseases and Sciences, 2002, 47, 1697-1704.	2.3	86

#	Article	IF	CITATIONS
55	Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. Digestive Diseases and Sciences, 1997, 42, 586-591.	2.3	84
56	Pancreatic Duct Stents in the Prophylaxis of Pancreatic Damage after Endoscopic Retrograde Cholangiopancreatography: A Systematic Analysis of Benefits and Associated Risks. Digestion, 2007, 75, 156-163.	2.3	84
57	NSAID and Aspirin Use by the Elderly in General Practice. Drugs and Aging, 2003, 20, 701-710.	2.7	82
58	Assessment of the agreement between wedge hepatic vein pressure and portal vein pressure in cirrhotic patients. Digestive and Liver Disease, 2005, 37, 601-608.	0.9	82
59	Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors. European Journal of Gastroenterology and Hepatology, 2005, 17, 745-751.	1.6	81
60	Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. Digestive and Liver Disease, 2000, 32, 763-768.	0.9	80
61	Contrast echocardiography for pulmonary arteriovenous malformations screening: does any bubble matter?. European Journal of Echocardiography, 2009, 10, 513-518.	2.3	79
62	Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. Journal of Hepatology, 1996, 24, 301-307.	3.7	78
63	The Multidimensional Prognostic Index Predicts Short- and Long-Term Mortality in Hospitalized Geriatric Patients With Pneumonia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2009, 64A, 880-887.	3.6	78
64	Probiotic monotherapy and <i>Helicobacter pylori </i> pooled-data analysis. World Journal of Gastroenterology, 2018, 24, 139-149.	3.3	78
65	Epidemiology of HCV Infection in the General Population: A Survey in a Southern Italian Town. American Journal of Gastroenterology, 2009, 104, 2740-2746.	0.4	77
66	Patients younger than 40 years with gastric carcinoma. Cancer, 1999, 85, 2506-2511.	4.1	74
67	Use of bovine lactoferrin for Helicobacter pylori eradication. Digestive and Liver Disease, 2003, 35, 706-710.	0.9	72
68	Quality of Life in Uncomplicated Symptomatic Diverticular Disease: Is It Another Good Reason for Treatment?. Digestive Diseases, 2007, 25, 252-259.	1.9	72
69	High prevalence of Helicobacter pylori infection in shepherds. Digestive Diseases and Sciences, 1999, 44, 1161-1164.	2.3	70
70	Protonâ€pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/nonâ€steroidal antiâ€inflammatory drugs. Alimentary Pharmacology and Therapeutics, 2004, 20, 1091-1097.	3.7	70
71	Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer, 1995, 76, 376-382.	4.1	67
72	Intrafamilial transmission of hepatitis delta virus: molecular evidence. Journal of Hepatology, 1999, 30, 564-569.	3.7	66

#	Article	IF	CITATIONS
73	The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. European Journal of Gastroenterology and Hepatology, 1997, 9, 951-956.	1.6	65
74	Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut, 2002, 50, 697-700.	12.1	65
75	Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia., 1998, 21, 1540-1542.		64
76	Helicobacter pylori in promotion of gastric carcinogenesis. Digestive Diseases and Sciences, 1996, 41, 950-955.	2.3	61
77	The effect of antibiotic resistance on the outcome of three 1â€week triple therapies against <i>Helicobacter pylori</i> . Alimentary Pharmacology and Therapeutics, 1999, 13, 667-673.	3.7	61
78	Connections Between Genetics and Clinical Data: Role of MCP-1, CFTR, and SPINK-1 in the Setting of Acute, Acute Recurrent, and Chronic Pancreatitis. American Journal of Gastroenterology, 2010, 105, 199-206.	0.4	61
79	Endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography in acute biliary pancreatitis. European Journal of Gastroenterology and Hepatology, 2011, 23, 367-374.	1.6	59
80	Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflammatory Bowel Diseases, 2018, 24, 1589-1596.	1.9	58
81	The impact of previous HBV infection on the course of chronic hepatitis C. American Journal of Gastroenterology, 2000, 95, 3529-3536.	0.4	57
82	Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver, 1994, 14, 175-181.	0.1	57
83	Functional Gastrointestinal Disorders and Eating Disorders: Relevance of the Association in Clinical Management. Scandinavian Journal of Gastroenterology, 1998, 33, 577-582.	1.5	56
84	Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study. Digestive and Liver Disease, 2000, 32, 667-672.	0.9	56
85	Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. Journal of Hepatology, 2013, 58, 962-968.	3.7	56
86	The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal antiinflammatory drugs: The role of gastroprotective drugs. Aging Clinical and Experimental Research, 2003, 15, 494-499.	2.9	55
87	Collagen proportionate area is an independent predictor of longâ€term outcome in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1214-1222.	3.7	55
88	Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Alimentary Pharmacology and Therapeutics, 2005, 21, 1435-1443.	3.7	53
89	Acid-related disorders in the elderly. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 839-848.	2.4	53
90	Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Alimentary Pharmacology and Therapeutics, 2000, 14, 1077-1082.	3.7	49

#	Article	IF	Citations
91	Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts. Hepatology, 1997, 26, 310-314.	7.3	48
92	A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology, 2001, 33, 989-993.	7.3	48
93	Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2006, 12, 7821.	3.3	48
94	Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. Alimentary Pharmacology and Therapeutics, 1996, 10, 1021-1027.	3.7	43
95	Short†and longâ€term therapy for reflux oesophagitis in the elderly: a multiâ€centre, placeboâ€controlled study with pantoprazole. Alimentary Pharmacology and Therapeutics, 2003, 17, 1399-1406.	3.7	43
96	Treatment Effects of Partially Hydrolyzed Guar Gum on Symptoms and Quality of Life of Patients with Irritable Bowel Syndrome. A Multicenter Randomized Open Trial. Digestive Diseases and Sciences, 2005, 50, 1107-1112.	2.3	43
97	Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. Alimentary Pharmacology and Therapeutics, 2006, 23, 1235-1240.	3.7	43
98	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.9	40
99	Ulcerative Colitis in Remission: Is It Possible to Predict the Risk of Relapse?. Digestion, 1989, 44, 217-221.	2.3	39
100	Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone―for the evaluation of "borderline―values. Journal of Hepatology, 1996, 25, 644-648.	3.7	39
101	Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Digestive Diseases and Sciences, 2001, 46, 1924-1936.	2.3	39
102	Efficacy of 5-ASA in the Treatment of Colonic Diverticular Disease. Journal of Clinical Gastroenterology, 2010, 44, 113-119.	2.2	39
103	Trends in adherence to the Mediterranean diet in South Italy: A cross sectional study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 410-417.	2.6	39
104	Combination therapy with amantadine and interferon in naıÌ^ve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. Journal of Hepatology, 2004, 40, 478-483.	3.7	38
105	A single-centre prospective, cohort study of the natural history of acute pancreatitis. Digestive and Liver Disease, 2015, 47, 205-210.	0.9	38
106	Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. Journal of Neurogastroenterology and Motility, 2020, 26, 16-28.	2.4	38
107	The Long-Term Clinical Outcome of Elderly Patients with Helicobacter pylori-Associated Peptic Ulcer Disease. Gerontology, 1998, 44, 153-158.	2.8	37
108	Liver transplantation: the Italian experience. Digestive and Liver Disease, 2002, 34, 640-648.	0.9	37

#	Article	IF	CITATIONS
109	â€~Serological biopsy' in firstâ€degree relatives of patients with gastric cancer affected by Helicobacter pylori infection. Scandinavian Journal of Gastroenterology, 2003, 38, 1223-1227.	1.5	37
110	Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Digestive and Liver Disease, 2004, 36, 666-670.	0.9	36
111	Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. Journal of Gastroenterology and Hepatology (Australia), 2003, 14, 468-475.	2.8	35
112	Use of Lactoferrin for Helicobacter pylori Eradication. Journal of Clinical Gastroenterology, 2003, 36, 396-398.	2.2	35
113	Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis. Transplant Infectious Disease, 2006, 8, 3-12.	1.7	35
114	Usefulness of the Comprehensive Geriatric Assessment in Older Patients with Upper Gastrointestinal Bleeding: A Two-Year Follow-Up Study. Digestive Diseases, 2007, 25, 124-128.	1.9	35
115	TIPS for refractory ascites: a single-centre experience. Journal of Gastroenterology, 2009, 44, 1089-1095.	5.1	35
116	Alexithymia and gastrointestinal-specific anxiety in moderate to severe irritable bowel syndrome. Comprehensive Psychiatry, 2014, 55, 1647-1653.	3.1	35
117	External Validation of Biochemical Indices for Noninvasive Evaluation of Liver Fibrosis in HCV Chronic Hepatitis. American Journal of Gastroenterology, 2005, 100, 868-873.	0.4	34
118	Monitoring surgical and medical outcomes: the Bernoulli cumulative SUM chart. A novel application to assess clinical interventions. Postgraduate Medical Journal, 2005, 81, 647-652.	1.8	33
119	Nonâ€selective betaâ€blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver International, 2017, 37, 1334-1344.	3.9	33
120	The role of alexithymia and gastrointestinal-specific anxiety as predictors of treatment outcome in irritable bowel syndrome. Comprehensive Psychiatry, 2017, 73, 127-135.	3.1	33
121	Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver International, 2008, 28, 370-376.	3.9	31
122	Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver International, 2007, 27, $612-619$ .	3.9	30
123	Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2020, 52, 374-391.	0.9	29
124	Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut, 2003, 52, 1543-1547.	12.1	28
125	Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. Fundamental and Clinical Pharmacology, 2005, 19, 497-501.	1.9	28
126	A comparison of kaolin-activated versus nonkaolin-activated thromboelastography in native and citrated blood. Blood Coagulation and Fibrinolysis, 2008, 19, 495-501.	1.0	28

#	Article	IF	CITATIONS
127	Efficacy of 5 MU of interferon in combination with ribavirin for naÄ±Ì ve patients with chronic hepatitis C virus: a randomized controlled trial. Journal of Hepatology, 2001, 34, 441-446.	3.7	27
128	Long-Term Clinical Outcome of Elderly Patients With Reflux Esophagitis: A Six-Month to Three-Year Follow-up Study. American Journal of Therapeutics, 2002, 9, 295-300.	0.9	27
129	NEMESIS: Noninferiority, Individual-Patient Metaanalysis of Selective Internal Radiation Therapy with <sup>90</sup> Y Resin Microspheres Versus Sorafenib in Advanced Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2020, 61, 1736-1742.	5.0	27
130	King's criteria, APACHE II, and SOFA scores in acute liver failure. Hepatology, 2006, 43, 881-881.	7.3	26
131	Cytotoxin-Associated Gene A-PositiveHelicobacter pylori Infection in the Elderly. Journal of Clinical Gastroenterology, 1998, 26, 18-22.	2.2	26
132	The Clinical Usefulness of Serum Pepsinogens, Specific IgG Antiâ€HP Antibodies and Gastrin for Monitoring ⟨i⟩Helicobacter pylori⟨i⟩ Treatment in Older People. Journal of the American Geriatrics Society, 1996, 44, 665-670.	2.6	24
133	Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. Alimentary Pharmacology and Therapeutics, 2001, 15, 1031-1036.	3.7	24
134	Atrophic gastritis: pathology and endoscopy in the reversibility assessment. Gut, 2003, 52, 1387-a-1388.	12.1	24
135	Hepatoblastoma: DNA nuclear content, proliferative indices, and pathology. Liver, 1998, 18, 128-133.	0.1	24
136	Terlipressin therapy for renal failure in cirrhosis. European Journal of Gastroenterology and Hepatology, 2010, 22, 481-486.	1.6	24
137	Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study. Digestive Diseases and Sciences, 2001, 46, 1409-1415.	2.3	23
138	Long-Term Outcome of Crohn's Disease Following Corticosteroid-Induced Remission. American Journal of Gastroenterology, 2007, 102, 814-819.	0.4	22
139	Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis. Cancer, 1991, 68, 1795-1798.	4.1	21
140	High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Journal of Hepatology, 2002, 37, 109-116.	3.7	21
141	Clinical Usefulness of Serum Pepsinogen II in the Management of <i>Helicobacter pylori</i> Infection. Digestion, 2004, 70, 167-172.	2.3	21
142	Effect of <i>Helicobacter pylori</i> Eradication on the Outcome of Reflux Esophagitis and Chronic Gastritis in the Elderly. Gerontology, 2006, 52, 99-106.	2.8	21
143	Diagnosis of chronic anaemia in gastrointestinal disorders: A guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP). Digestive and Liver Disease, 2019, 51, 471-483.	0.9	21
144	Meta-analysis of the impact of SPINK1 p.N34S gene variation in Caucasic patients with chronic pancreatitis. An update. Digestive and Liver Disease, 2017, 49, 847-853.	0.9	20

#	Article	IF	CITATIONS
145	Lack of association between Helicobacter pylori infection and extracardiac atherosclerosis in dyspeptic elderly subjects. Age and Ageing, 1999, 28, 367-371.	1.6	19
146	Antibody response to Helicobacter pylori CagA and heat-shock proteins in determining the risk of gastric cancer development. Digestive and Liver Disease, 2000, 32, 378-383.	0.9	19
147	Influence of Helicobacter pylori infection on severity of oesophagitis and response to therapy in the elderly. Digestive and Liver Disease, 2002, 34, 328-331.	0.9	19
148	Treatment of patients with HCV infection with or without liver biopsy. Journal of Viral Hepatitis, 2004, 11, 536-542.	2.0	19
149	Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World Journal of Gastroenterology, 2007, 13, 4467.	3.3	19
150	Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified <scp>EEG</scp> study. Liver International, 2015, 35, 1524-1532.	3.9	19
151	IBS clinical management in Italy: The AIGO survey. Digestive and Liver Disease, 2019, 51, 782-789.	0.9	19
152	Short-term treatment of gastric ulcer. Digestive Diseases and Sciences, 1996, 41, 1108-1131.	2.3	18
153	Long-term follow-up of achalasic patients treated with botulinum toxin. Ecological Management and Restoration, 2000, 13, 96-101.	0.4	18
154	Cardiovascular morbidity and mortality is increased postâ€liver transplantation even in recipients with no preâ€existing risk factors. Liver International, 2019, 39, 1557-1565.	3.9	18
155	Small intestinal bacterial overgrowth and irritable bowel syndrome. American Journal of Gastroenterology, 2003, 98, 2572.	0.4	17
156	Natural Course of Functional Dyspepsia After Helicobacter pyloriEradication: A Seven-Year Survey. Digestive Diseases and Sciences, 2005, 50, 2286-2295.	2.3	16
157	Effects of interferon plus ribavirin treatment on NF- $\hat{l}^{9}$ B, TGF- $\hat{l}^{2}$ 1, and metalloproteinase activity in chronic hepatitis C. Modern Pathology, 2006, 19, 1047-1054.	5.5	16
158	Dyspepsia and Helicobacter pylori infection: a prospective multicentre observational study. Digestive and Liver Disease, 2003, 35, 157-164.	0.9	15
159	Management and prognosis of hepatocellular carcinoma in the elderly: Results of an inâ€field multicenter cohort study. Liver International, 2017, 37, 1184-1192.	3.9	15
160	Stomach-partitioning gastrojejunostomy is better than conventional gastrojejunostomy in palliative care of gastric outlet obstruction for gastric or pancreatic cancer: a meta-analysis. Journal of Gastrointestinal Oncology, 2019, 10, 283-291.	1.4	15
161	The dark side of the gastric biopsy. Human Pathology, 1999, 30, 741-744.	2.0	14
162	Serotonin gene polymorphisms and lifetime mood disorders in predicting interferon-induced depression in chronic hepatitis C. Journal of Affective Disorders, 2015, 183, 90-97.	4.1	14

#	Article	IF	Citations
163	Antagonism to calcium antagonists. Lancet, The, 1996, 347, 1761-1762.	13.7	13
164	Bowel Obsession Syndrome in a Patient With Ulcerative Colitis. Psychosomatics, 2007, 48, 448-450.	2.5	13
165	Nuclear DNA content and pathology in radically treated pancreatic carcinoma: The prognostic significance of DNA ploidy, histology and nuclear grade. , 1996, 77, 459-466.		12
166	Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B. Journal of Viral Hepatitis, 1999, 6, 429-434.	2.0	12
167	The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon. Journal of Viral Hepatitis, 1995, 2, 171-174.	2.0	11
168	Efficacy of Loco-Regional Ablation Therapy of HCC in a Population of Liver Transplanted Patients. Digestive Diseases and Sciences, 2008, 53, 1131-1137.	2.3	11
169	Undernutrition, risk of malnutrition and obesity in gastroenterological patients: A multicenter study. World Journal of Gastrointestinal Oncology, 2016, 8, 563.	2.0	11
170	Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly?. Digestive Diseases and Sciences, 1996, 41, 17-21.	2.3	10
171	Cure of Helicobacter pylori-positive active duodenal ulcer patients: double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. Digestive and Liver Disease, 2000, 32, 108-115.	0.9	10
172	Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study. Alimentary Pharmacology and Therapeutics, 2004, 19, 331-337.	3.7	10
173	Endoscopic Treatment of Gastroesophageal Reflux Disease. Endoscopy, 2005, 37, 470-478.	1.8	10
174	Hepatitis C virus serotypes and liver pathology. Liver, 1996, 16, 353-357.	0.1	10
175	Distinct associations of DSM-5 Somatic Symptom Disorder, the Diagnostic Criteria for Psychosomatic Research-Revised (DCPR-R) and symptom severity in patients with irritable bowel syndrome. General Hospital Psychiatry, 2020, 64, 56-62.	2.4	10
176	Helicobacter pylori infection in elderly patients with peptic ulcer. Age and Ageing, 1999, 28, 412-414.	1.6	9
177	IN VITRO EFFECTS OF NALOXONE ON T-LYMPHOCYTE-DEPENDENT ANTIBACTERIAL ACTIVITY IN HEPATITIS C VIRUS (HCV) INFECTED PATIENTS AND IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS. Immunopharmacology and Immunotoxicology, 2001, 23, 1-11.	2.4	9
178	Role of endogenous endothelin-1 in ethanol-induced gastric mucosal damage in humans. Digestive Diseases and Sciences, 2003, 48, 663-669.	2.3	9
179	The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment. Comprehensive Psychiatry, 2015, 60, 17-25.	3.1	9
180	Ursodeooxycholic acid for primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 352-353.	3.7	8

#	Article	IF	Citations
181	Rabeprazole in a one-week eradication therapy of Helicobacter pylori: Comparison of different dosages. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 783-786.	2.8	8
182	Helicobacter pylori infection and the risk of gastro-duodenal damage in symptomatic elderly chronic low-dose aspirin users: effect of antisecretory drugs. Age and Ageing, 2004, 33, 402-404.	1.6	8
183	Somatization Symptoms or Interferon-Related Adverse Events? Alexithymia and Somatization in Somatic Symptom Reporting of Patients with Chronic Hepatitis C. Psychotherapy and Psychosomatics, 2014, 83, 310-311.	8.8	8
184	Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis. Pancreas, 2017, 46, 225-229.	1.1	8
185	Genetic Associations of Alexithymia in Predicting Interferon-Induced Depression in Chronic Hepatitis C. Psychopathology, 2015, 48, 417-420.	1.5	7
186	Patients younger than 40 years with gastric carcinoma. Cancer, 1999, 85, 2506-2511.	4.1	7
187	$\hat{l}_{\pm}$ -Fetoprotein, tissue polypeptide antigen and ferritin in diagnosing primary hepatocellular carcinoma in patients with liver cirrhosis. Journal of Cancer Research and Clinical Oncology, 1989, 115, 276-278.	2.5	6
188	Markers of slow-healing peptic ulcer in the elderly. Digestive Diseases and Sciences, 1993, 38, 1414-1421.	2.3	6
189	Association of Apolipoprotein E and Angiotensin Converting Enzyme Gene Polymorphisms with the Multidimensional Impairment in Older Patients. Rejuvenation Research, 2009, 12, 239-247.	1.8	6
190	Fatty liver and mortality: a cohort population study in South Italy. BMJ Open, 2019, 9, e027379.	1.9	6
191	Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign. Internal and Emergency Medicine, 2019, 14, 301-308.	2.0	6
192	Correspondence. Cancer, 1993, 71, 510-511.	4.1	5
193	Systematic Review of HVPG Measurement: Statistics Versus Clinical Applicability. Gastroenterology, 2007, 132, 1201-1202.	1.3	5
194	How to interpret a randomized controlled study stopped early. Intensive Care Medicine, 2013, 39, 1642-1643.	8.2	5
195	Serum pepsinogens as markers of Helicobacter pylori eradication. Current Therapeutic Research, 1995, 56, 777-786.	1.2	4
196	Optimal PPIâ€based Triple Therapy for the Cure of Helicobacter pylori Infection: A Single Center Comparison of Four 14â€day Schedules. Helicobacter, 1998, 3, 115-119.	3.5	4
197	Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding. Annals of Internal Medicine, 2004, 141, 78.	3.9	4
198	Pepsin concentration in gastroduodenal biopsy homogenates in chronic ulcer disease. Digestive Diseases and Sciences, 1994, 39, 301-308.	2.3	3

#	Article	IF	CITATIONS
199	Direct antiviral agents and risk of HCC: Waiting for Godot. Journal of Hepatology, 2018, 68, 614-616.	3.7	3
200	Gender equality in medicine: What do gastroenterologists from Italy think of it?. Digestive and Liver Disease, 2018, 50, 725-727.	0.9	3
201	Hospital admission for digestive diseases: Gastroenterology units offer a more effective and efficient care. Digestive and Liver Disease, 2019, 51, 43-46.	0.9	3
202	Effects of chronic therapy with non-steroideal antinflammatory drugs on gastric permeability of sucrose: A study on 71 patients with rheumatoid arthritis. World Journal of Gastroenterology, 2006, 12, 5017.	3.3	3
203	Predictive model of response to therapy with interferon in patients with chronic hepatitis B virus infection: A methodological note. Hepatology, 1990, 12, 180-181.	7.3	2
204	Reply to Dr. Barkun's Letter. American Journal of Gastroenterology, 2005, 100, 2133-2134.	0.4	2
205	Malignant ascites. European Journal of Gastroenterology and Hepatology, 1993, 5, 251-256.	1.6	1
206	Omeprazole in the maintenance treatment of duodenal ulcer: results after 6 months of 20 mg daily, 20 mg every other day, or 40 mg on weekends. Current Therapeutic Research, 1996, 57, 33-41.	1.2	1
207	The Italian experience on paediatric liver transplantation: 1988–1999 report. Digestive and Liver Disease, 2002, 34, 649-655.	0.9	1
208	Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy. Journal of Viral Hepatitis, 1999, 6, 373-380.	2.0	0